- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Renal Cell Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cavity Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- AFP464, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 2,840
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- Herceptin, GM-CSF
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, biopsy
- Biological · Drug · Other + 1 more
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer
- Interventions
- filgrastim, monoclonal antibody m170, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, yttrium Y 90 monoclonal antibody m170
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, Inflammatory Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
- Interventions
- tamoxifen citrate, busulfan, thiotepa, melphalan, aldesleukin, sargramostim, peripheral blood stem cell transplantation, radiation therapy
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2009
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
- Interventions
- alemtuzumab, methylprednisolone, tacrolimus
- Biological · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 6
- States / cities
- New York, New York • Cleveland, Ohio • Portland, Oregon + 2 more
- Conditions
- Breast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
- Interventions
- entinostat, exemestane, Placebo
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 24
- States / cities
- Greenbrae, California • La Jolla, California • Aurora, Colorado + 20 more
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
- Interventions
- Standard Genetic Counseling, Educational Video
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Brighton, Massachusetts • Milford, Massachusetts + 3 more
- Conditions
- Post Menopausal, Hormone Receptor Positive Breast Cancer
- Interventions
- TAK700
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, vinorelbine, trastuzumab
- Drug
- Lead sponsor
- Harold J. Burstein, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 7
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Lowell, Massachusetts + 1 more
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Metastatic Breast Cancer, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Triple Negative Breast Cancer
- Interventions
- Pembrolizumab, Cisplatin
- Biological · Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Melanoma
- Interventions
- 852A
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 2
- States / cities
- Lebanon, New Hampshire • Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- trastuzumab, paclitaxel
- Biological · Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
- Interventions
- AVA6000
- Drug
- Lead sponsor
- Avacta Life Sciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas • Seattle, Washington
- Conditions
- Metastatic Breast Cancer, Ovarian Cancer
- Interventions
- Not listed
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Minneapolis, Minnesota
- Conditions
- Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
- Interventions
- Iodine-124, PET/CT with Iodine-124
- Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cancer
- Interventions
- entinostat
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors With and Without Brain Metastases
- Interventions
- ANG1005
- Drug
- Lead sponsor
- Angiochem Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Houston, Texas • San Antonio, Texas
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Melanoma (Skin), Metastatic Cancer, Ovarian Cancer, Pancreatic Cancer
- Interventions
- cyclophosphamide, poly ICLC, hepatic artery embolization, 3-dimensional conformal radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Stage IV Melanoma
- Interventions
- Disulfiram (DSF)
- Drug
- Lead sponsor
- John P. Fruehauf
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Metastatic Melanoma
- Interventions
- IMO-2125, Ipilimumab
- Drug
- Lead sponsor
- Idera Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • Tampa, Florida • Iowa City, Iowa + 7 more
- Conditions
- Neoplasms
- Interventions
- GSK525762, Placebo, Fulvestrant
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Melanoma
- Interventions
- Relatlimab, Ipilimumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 4 more
- Conditions
- Breast Cancer, Metastases
- Interventions
- Ixabepilone + Capecitabine, Capecitabine
- Drug
- Lead sponsor
- R-Pharm
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 32
- States / cities
- Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more